These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38542228)

  • 1. Inhibitor Trapping in Kinases.
    Spassov DS; Atanasova M; Doytchinova I
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
    Dai Y; Rahmani M; Corey SJ; Dent P; Grant S
    J Biol Chem; 2004 Aug; 279(33):34227-39. PubMed ID: 15175350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
    Härtel N; Klag T; Hanfstein B; Mueller MC; Schenk T; Erben P; Hochhaus A; La Rosée P
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):203-12. PubMed ID: 22089930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases.
    Warmuth M; Simon N; Mitina O; Mathes R; Fabbro D; Manley PW; Buchdunger E; Forster K; Moarefi I; Hallek M
    Blood; 2003 Jan; 101(2):664-72. PubMed ID: 12393636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.
    Pene-Dumitrescu T; Smithgall TE
    J Biol Chem; 2010 Jul; 285(28):21446-57. PubMed ID: 20452982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl.
    Gu JJ; Santiago L; Mitchell BS
    Blood; 2005 Apr; 105(8):3270-7. PubMed ID: 15604220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL.
    Preyer M; Vigneri P; Wang JY
    PLoS One; 2011 Feb; 6(2):e17020. PubMed ID: 21347248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
    Nguyen TK; Rahmani M; Harada H; Dent P; Grant S
    Blood; 2007 May; 109(9):4006-15. PubMed ID: 17218385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.
    Seeliger MA; Ranjitkar P; Kasap C; Shan Y; Shaw DE; Shah NP; Kuriyan J; Maly DJ
    Cancer Res; 2009 Mar; 69(6):2384-92. PubMed ID: 19276351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.
    Morinaga K; Yamauchi T; Kimura S; Maekawa T; Ueda T
    Int J Cancer; 2008 Jun; 122(11):2621-7. PubMed ID: 18338755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia.
    Cooper MJ; Cox NJ; Zimmerman EI; Dewar BJ; Duncan JS; Whittle MC; Nguyen TA; Jones LS; Ghose Roy S; Smalley DM; Kuan PF; Richards KL; Christopherson RI; Jin J; Frye SV; Johnson GL; Baldwin AS; Graves LM
    PLoS One; 2013; 8(6):e66755. PubMed ID: 23826126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases.
    Lin YL; Roux B
    J Am Chem Soc; 2013 Oct; 135(39):14741-53. PubMed ID: 24001034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.
    Young MA; Shah NP; Chao LH; Seeliger M; Milanov ZV; Biggs WH; Treiber DK; Patel HK; Zarrinkar PP; Lockhart DJ; Sawyers CL; Kuriyan J
    Cancer Res; 2006 Jan; 66(2):1007-14. PubMed ID: 16424036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
    Yokota A; Kimura S; Masuda S; Ashihara E; Kuroda J; Sato K; Kamitsuji Y; Kawata E; Deguchi Y; Urasaki Y; Terui Y; Ruthardt M; Ueda T; Hatake K; Inui K; Maekawa T
    Blood; 2007 Jan; 109(1):306-14. PubMed ID: 16954504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming kinase resistance in chronic myeloid leukemia.
    Lee F; Fandi A; Voi M
    Int J Biochem Cell Biol; 2008; 40(3):334-43. PubMed ID: 18401881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.
    Wu J; Meng F; Lu H; Kong L; Bornmann W; Peng Z; Talpaz M; Donato NJ
    Blood; 2008 Apr; 111(7):3821-9. PubMed ID: 18235045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells.
    Ciarcia R; Damiano S; Montagnaro S; Pagnini U; Ruocco A; Caparrotti G; d'Angelo D; Boffo S; Morales F; Rizzolio F; Florio S; Giordano A
    Cell Cycle; 2013 Sep; 12(17):2839-48. PubMed ID: 23966159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
    Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
    Tseng PH; Lin HP; Zhu J; Chen KF; Hade EM; Young DC; Byrd JC; Grever M; Johnson K; Druker BJ; Chen CS
    Blood; 2005 May; 105(10):4021-7. PubMed ID: 15665113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines.
    Gwanmesia PM; Romanski A; Schwarz K; Bacic B; Ruthardt M; Ottmann OG
    BMC Cancer; 2009 Feb; 9():53. PubMed ID: 19216789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.